Skip to main
NGNE
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc is demonstrating improved confidence in its pipeline, particularly with its lead candidate NGN-401 for Rett syndrome, supported by enhancements in managing HLH reactions through better monitoring techniques. The company’s proprietary EXACTTM technology positions it well in the competitive landscape of genetic medicines for rare neurological diseases, which presents a significant market opportunity given the high unmet medical needs in this area. Consequently, positive developments in clinical trials and management capability have contributed to an optimistic outlook for Neurogene's operational and financial performance.

Bears say

Neurogene Inc's financial outlook is adversely affected by the potential clinical failure of its key drug candidates, which could severely disrupt the company's ability to raise necessary capital for continued operations and development. Additionally, negative investor sentiment regarding drug pricing, mergers and acquisitions, and overall sector valuations could further diminish the company's market valuation. The outlined downside scenario suggests that if Neurogene fails to establish a credible registrational trial or encounters safety concerns, the repercussions could significantly impact its stock performance, with projections indicating a potential drop to $8.

Neurogene Inc (NGNE) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 6 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Oct 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.